Timmins; Peter
Patent Applications and Registrations
Patent applications and USPTO patent grants for Timmins; Peter.The latest application filed is for "solid tablet dosage form of ridinilazole".
- Timmins; Peter - Little Sutton GB
- TIMMINS; Peter - Cheshire GB
- Timmins; Peter - Moreton GB
- Timmins; Peter - Prenton GB
- Timmins; Peter - Princeton NJ
- Timmins; Peter - Wirral N/A GB
- Timmins, Peter - Merseyside GB
- Timmins; Peter - Irby GB
- Timmins; Peter - Morton Wirral GB
| Patent | Date |
|---|---|
| Solid Tablet Dosage Form Of Ridinilazole App 20220226249 - Wilson; Francis X. ; et al. | 2022-07-21 |
| Amorphous Form Of 5-bromopyridin-3-yl 3-deoxy-3-[4-(3,4,5-trifluorophenyl)-1h-1,2,3-triazol-1-yl]-1-thio-alpha-- D-galactopyranoside App 20220064204 - GRAVELLE; Lise ; et al. | 2022-03-03 |
| Bilayer Tablet Formulations App 20170333353 - Abebe; Admassu ; et al. | 2017-11-23 |
| Bilayer tablet formulations Grant 9,616,028 - Abebe , et al. April 11, 2 | 2017-04-11 |
| Bilayer Tablet Formulations App 20150238421 - Abebe; Admassu ; et al. | 2015-08-27 |
| Stable Pharmaceutical Composition For Optimized Delivery Of An Hiv Attachment Inhibitor App 20150158891 - Brown; Jonathan R. ; et al. | 2015-06-11 |
| Bilayer tablet formulations Grant 9,050,258 - Abebe , et al. June 9, 2 | 2015-06-09 |
| Reduced Mass Metformin Formulations App 20140335170 - Abebe; Admassu ; et al. | 2014-11-13 |
| Bilayer Tablet Formulations App 20130330406 - Abebe; Admassu ; et al. | 2013-12-12 |
| Bilayer tablet formulations Grant 8,535,715 - Abebe , et al. September 17, 2 | 2013-09-17 |
| Reduced Mass Metformin Formulations App 20120294936 - Abebe; Admassu ; et al. | 2012-11-22 |
| Bilayer Tablet Formulations App 20120282336 - Abebe; Admassu ; et al. | 2012-11-08 |
| Stable Pharmaceutical Composition For Optimized Delivery Of An Hiv Attachment Inhibitor App 20100056540 - Brown; Jonathan R. ; et al. | 2010-03-04 |
| Multilayered tablet containing pravastatin and aspirin and method App 20040115265 - Benkerrour, Loutfy ; et al. | 2004-06-17 |
| Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method Grant 6,660,300 - Timmins , et al. December 9, 2 | 2003-12-09 |
| Biphasic controlled release delivery system for high solubility pharmaceuticals and method Grant 6,475,521 - Timmins , et al. November 5, 2 | 2002-11-05 |
| Nefazodone dosage form Grant 6,143,325 - Dennis , et al. November 7, 2 | 2000-11-07 |
| Salts of metformin and method Grant 6,031,004 - Timmins , et al. February 29, 2 | 2000-02-29 |
| Buoyant controlled release powder formulation Grant 5,169,638 - Dennis , et al. December 8, 1 | 1992-12-08 |
| Complex of anti-fungal agent and cyclodextrin and method Grant 4,883,785 - Chow , et al. November 28, 1 | 1989-11-28 |
| Steroid cream formulation Grant 4,883,792 - Timmins , et al. November 28, 1 | 1989-11-28 |
| Controlled release formulation Grant 4,792,452 - Howard , et al. December 20, 1 | 1988-12-20 |
| Method of preparing liposomes and products produced thereby Grant 4,744,989 - Payne , et al. May 17, 1 | 1988-05-17 |
| Alkylammonium complexes of diatrizoic acid as X-ray contrast agents Grant 4,735,795 - Robinson , et al. April 5, 1 | 1988-04-05 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 